Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
August-2014 Volume 10 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2014 Volume 10 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells

  • Authors:
    • Junfang Wu
    • Jie Niu
    • Xiaopeng Li
    • Tongming Ren
    • Fenxi Zhang
  • View Affiliations / Copyright

    Affiliations: Laboratory of Morphology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Ophthalmology, The Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Anatomy, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
  • Pages: 955-958
    |
    Published online on: May 29, 2014
       https://doi.org/10.3892/mmr.2014.2286
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

It is well established that mesenchymal stem cells (MSCs) will partially lose their proliferative ability with continuous expansion. However, the specific mechanisms underlying this effect remain unclear. In the present study, it was identified that β-catenin was downregulated in the late passage (passage 8) of bone marrow mesenchymal stem cells (bmMSCs). Following β-catenin expression, the expression of phospho-Akt was also significantly decreased in the late passage of bmMSCs. More notably, overexpression of β-catenin in passage 8 of bmMSCs by transfection with pMXs-β-catenin plasmids, significantly increased cell proliferation and Akt expression. These results indicate that the downregulation of β-catenin and Akt signaling may be a critical factor for the proliferation of the late passage of bmMSCs.

Introduction

Bone marrow mesenchymal stem cells (bmMSCs) are a type of multipotent stem cells that are capable of differentiating into multiple cell types, including osteoblasts, chondrocytes, adipocytes, cardiomyocytes and neurons (1,2). Currently, bmMSCs are widely utilized in regenerative medicine. The proliferative ability of bmMSCs is the most important determinant for the efficiency of bmMSC-based transplantation therapy (1,3). Previous studies have demonstrated that bmMSCs may lose their proliferative ability with consecutive expansion (4). However, why the late passages of bmMSCs have low proliferative ability remains unclear.

The Wnt/β-catenin signaling pathway has a critical role in cell proliferation. The upregulation of Wnt/β-catenin signals stimulates cell proliferation and improves cell survival (5,6). Akt is also an important regulator for cell proliferation and survival (7). Previous studies have demonstrated that downregulation and deficiency of Akt impairs cell proliferation (8,9). In the preliminary study, we observed that β-catenin and Akt were markedly downregulated in the late (8th) passage of bmMSCs. Therefore, it was hypothesized that the downregulation of β-catenin and Akt signals may be important in regulating the proliferative ability of the late passage of bmMSCs and the present study was designed to address this hypothesis.

Materials and methods

Materials and reagents

Dulbecco’s Modified Eagle Medium (DMEM), Lipofectamine® 2000, DNase I, RNeasy Mini kit and SuperScript II First Strand DNA Synthesis kit were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA) and the 2X PCR Reaction Mix was obtained from Sigma-Aldrich (St. Louis, MO, USA). HyClone fetal bovine serum (FBS) and ECL western blotting substrate was purchased from Thermo Fisher Scientific Inc. (Cleveland, OH, USA). Rabbit anti-mouse β-catenin antibody was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Phospho-Akt and β-actin primary antibodies, as well as HRP-conjugated goat anti-rabbit secondary antibody were obtained from Abcam (Cambridge, MA, USA). Precision Plus Protein prestained standards were purchased from Bio-Rad (Hercules, CA, USA). The PVDF membrane was obtained from GE Healthcare (Pittsburgh, PA, USA).

Cell culture and study protocol

BmMSCs were obtained and cultured as previously described (1,10). Passage 2 and passage 8 of cells were used in the experiments. The present study was approved by the Ethics Committee of Xinxiang Medical University (Xinxiang, China).

Cell counting

The passage 2 and passage 8 of bmMSCs were plated in 24-well plates (4 wells/group). Cells were collected on days 2, 4, 6, 8, 10 and 12, and counted under a microscope (Olympus, Tokyo, Japan). The cell growth curve was drawn according to the average cell number of each group.

Western blot analysis

Western blotting was performed following the standard procedure. Proteins were extracted from passage 2 and passage 8 of bmMSCs and separated by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis. Following the electrophoresis, proteins were transferred to the polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% milk or 5% bovine serum albumin (BSA) in Tris-buffered saline with Tween-20 (TBS-T), and then incubated with β-catenin or phospho-Akt primary antibodies at 4°C overnight. Following three times washing with TBS-T, the blots were incubated with β-actin antibody at room temperature for 1 h. Then, the blots were washed with TBS-T and incubated with HRP-conjugated secondary antibody at room temperature for 1 h. The immunoreactive bands were visualized by enhanced chemiluminescence, and the images were scanned using a Gel Imaging Analysis System (Bio-Rad, Hercules, CA, USA).

Reverse transcription polymerase chain reaction (RT-PCR) assay

In the present study, expression of Akt1 in passage 8 of bmMSCs was measured using RT-PCR assay following transfection of the cells with pMXs-β-catenin plasmids. The procedures of RNA extraction and RT-PCR reaction were conducted as previously described (10). The primers used were 5′-GTCTCTAGGGTCCAGGGCCAAAGTC-3′ (Akt1 forward) and 5′-CATCTAAAAGGACAAGTGCTAGGAG-3′ (Akt1 reverse); 5′-TTCTTTGCAGCTCCTTCGTTGCCG-3′ (β-actin forward) and 5′-TGGATGGCTACGTACATGGCTGGG-3′ (β-actin reverse).

β-catenin overexpression in passage 8 bmMSCs

Passage 8 bmMSCs were plated in 6-well plates. As the cells reached 80% confluency, they were transfected with pMXs-β-catenin plasmids using Lipofectamine® 2000. The cells transfected with empty pMXs plasmids served as controls.

Statistical analysis

Statistical analysis was performed with SPSS 11.5 software (SPSS, Inc., Chicago, IL, USA). Data are presented as the mean ± SD from four independent experiments. Univariate comparisons of the means were evaluated using the Student’s t-test and/or one-way ANOVA with Tukey’s post-hoc adjustment for multiple comparisons when appropriate. P<0.05 was considered to indicate a statistically significant difference.

Results

Proliferation of passage 2 and passage 8 bmMSCs

As illustrated in Fig. 1, the cell growth curve revealed that the cell numbers of passage 8 bmMSCs following plating for 2, 4, 6, 8, 10 and 12 days was significantly lower than the numbers of passage 2 cells (P<0.05). This demonstrates that the late passage of bmMSCs have a lower proliferative ability than the early passage of cells.

Figure 1

Growth curve illustrates the proliferation of P2 and P8 bmMSCs. Error bars represent the mean ± SD (four independent experiments/group). *P<0.05 vs. passage 8 cells. bmMSCs, bone marrow mesenchymal stem cells; P, passage.

Expression of β-catenin and Akt in passage 2 and passage 8 bmMSCs

Western blotting analysis demonstrated that expression of β-catenin and phospho-Akt was markedly decreased (P<0.05) in passage 8 bmMSCs as compared with passage 2 cells (Fig. 2).

Figure 2

Expression of β-catenin and phospho-Akt in passage 2 and passage 8 bmMSCs. Bar graphs represent the mean ± SD (four independent experiments/group). *P<0.05 vs. passage 2 cells. bmMSCs, bone marrow mesenchymal stem cells.

Expression of β-catenin and Akt in passage 8 bmMSCs following transfection with pMXs-β-catenin plasmids

As illustrated in Fig. 3, the western blot analysis revealed that the expression of β-catenin was markedly increased (P<0.05) in passage 8 bmMSCs transfected with pMXs-β-catenin plasmids as compared with the cells transfected with empty pMXs plasmids. More notably, another cell proliferation signal Akt (Akt1 mRNA) was also markedly upregulated (P<0.05) in passage 8 bmMSCs transfected with pMXs-β-catenin plasmids.

Figure 3

Western blot analysis and RT-PCR assays demonstrate β-catenin protein and Akt1 mRNA expression in passage 8 bmMSCs following transfection with empty pMXs plasmids and pMXs-β-catenin plasmids. Bar graphs represent the mean ± SD (four independent experiments/group). *P<0.05 vs. transfection with empty plasmids. bmMSCs, bone marrow mesenchymal stem cells; RT-PCR, reverse transcription-polymerase chain reaction.

Cell proliferation following transfection of pMXs-β-catenin plasmids

As illustrated in Fig. 4, cell counting demonstrated that proliferation of passage 8 bmMSCs was significantly increased following transfection with pMXs-β-catenin plasmids as compared with the cells transfected with empty pMXs plasmids (P<0.05).

Figure 4

Cell proliferation following transfection with empty pMXs plasmids and pMXs-β-catenin plasmids for 24 h. Bar graphs represent the mean ± SD (four independent experiments/group). *P<0.05 vs. transfection with empty plasmids.

Discussion

In the present study, it was demonstrated for the first time, to the best of our knowledge, that β-catenin and Akt expression are involved in the weak proliferative ability of the late passage of bmMSCs. The results revealed that β-catenin and Akt were markedly downregulated in the late passage (passage 8) of bmMSCs as compared with the early passage (passage 2). Overexpression of β-catenin in the late passage of bmMSCs increased their proliferation and Akt expression.

bmMSCs are the promising source of seed cells for stem cell transplant therapy. The proliferative ability of bmMSCs is the most important determinant of bmMSC-based therapeutic efficiency. Previous studies have demonstrated that the late passages of MSCs will partially lose their proliferative ability (4). As is consistent with previous studies, we also observed that the proliferation of the late passage (passage 8) of bmMSCs was markedly lower than the early passage (passage 2) cells.

More importantly, we identified that the expression of β-catenin was notably downregulated in the late passage of bmMSCs. β-catenin is a dual function protein that mainly regulates cell-cell adhesion and gene transcription. The expression of Wnt/β-catenin signals has also been implicated in the proliferation of numerous cell types, including MSCs (11,12). It has been demonstrated that stimulation of Wnt/β-catenin signaling with its agonists promotes proliferation of MSCs (13). Downregulation or deficiency of β-catenin was also identified to inhibit the proliferative ability of other cell types (14). In the present study, we hypothesized that the downregulation of β-catenin may be responsible for the weak proliferation of the late passage of bmMSCs. Our further experiments confirmed this, which suggests that overexpression of β-catenin in the late passage of bmMSCs enhances their proliferative ability.

Akt is a serine/threonine-specific protein kinase that is important in numerous cell physiological processes, including cell metabolism, proliferation, migration, autophagy and apoptosis (7,15,16). Akt is known as a cell survival signal and activation of the PI3K/Akt pathway has been observed to promote proliferation of bmMSCs (17). In the present study, we identified that phospho-Akt expression was significantly decreased in the late passage of bmMSCs following the expression of β-catenin. Previous studies have demonstrated that Akt regulates expression of β-catenin and the β-catenin signaling also participates in the regulation of Akt expression (18–20). Furthermore, it appears β-catenin regulates cell proliferation via activation of the PI3K/Akt pathway (21). In the present study, overexpression of β-catenin in the late passage of bmMSCs also enhanced Akt1 expression.

In conclusion, these data revealed that β-catenin and Akt were markedly downregulated in passage 8 bmMSCs and that the proliferative ability of passage 8 bmMSCs was significantly lower than passage 2 bmMSCs. Transfection of β-catenin cDNA in passage 8 bmMSCs enhanced the proliferation of these cells and increased Akt expression. These results indicate that Wnt/β-catenin and Akt signals have an important role in the regulation of bmMSC growth.

Acknowledgements

This study was supported by a grant from the National Natural Science Foundation of China (no. 81370428).

References

1 

Zhang F, Wang C, Jing S, et al: Lectin-like oxidized LDL receptor expresses in mouse bone marrow-derived mesenchymal stem cells and stimulates their proliferation. Exp Cell Res. 319:1054–1059. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Ferroni L, Gardin C, Tocco I, et al: Potential for neural differentiation of mesenchymal stem cells. Adv Biochem Eng Biotechnol. 129:89–115. 2013.PubMed/NCBI

3 

Meligy FY, Shigemura K, Behnsawy HM, et al: The efficiency of in vitro isolation and myogenic differentiation of MSCs derived from adipose connective tissue, bone marrow, and skeletal muscle tissue. In Vitro Cell Dev Biol Anim. 48:203–215. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Boroujeni ME, Gowda P, Johnson J, et al: The proliferation and differentiation capacity of bone marrow derived-human mesenchymal stem cells in early and late doubling. Asian J Biochem. 7:27–36. 2012. View Article : Google Scholar

5 

Masckauchán TN, Shawber CJ, Funahashi Y, et al: Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis. 8:43–51. 2005.PubMed/NCBI

6 

Sarkar S, Swiercz R, Kantara C, et al: Annexin A2 mediates up-regulation of NF-κB, β-catenin, and stem cell in response to progastrin in mice and HER-293 cells. Gastroenterology. 140:583–595. 2011.PubMed/NCBI

7 

Xu J, Qian J, Xie X, et al: High density lipoprotein cholesterol promotes the proliferation of bone-derived mesenchymal stem cells via binding scavenger receptor-B type I and activation of PI3K/Akt, MAPK/ERK1/2 pathwys. Mol Cell Biochem. 371:55–64. 2012. View Article : Google Scholar

8 

Skeen JE, Bhaskar PT, Chen CC, et al: Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 10:269–280. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Priore R, Dailey L and Basilico C: Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. J Cell Physiol. 207:800–808. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Zhang F, Jing S, Ren T, et al: MicroRNA-10b promotes migration of mouse bone marrow-derived mesenchymal stem cells and downregulates E-cadherin expression. Mol Med Rep. 8:1084–1088. 2013.PubMed/NCBI

11 

Chen BY, Wang X, Chen LW and Luo ZJ: Molecular targeting regulation of proliferation and differentiation of bone marrow-derived mesenchymal stem cells or mesenchymal stromal cells. Curr Drug Targets. 13:561–571. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Wang Y, Chen X, Zhu W, et al: Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol. 33:696–701. 2006. View Article : Google Scholar : PubMed/NCBI

13 

Hoffman MD and Brnoit DS: Agonism of Wnt-β-catenin signaling promotes mesenchymal stem cell (MSC) expansion. J Tissue Eng Regen Med. Apr 1–2013.(Epub ahead of print).

14 

Foo C, Frey S, Yang HH, et al: Downregulation of beta-catenin and transdifferentiation of human osteoblast to adipocytes under estrogen deficiency. Gynecol Endocrinol. 23:535–540

15 

Zhang F, Hong Y, Liang W, et al: Co-culture with Sertoli cells promotes proliferation and migration of umbilical cord mesenchyaml stem cells. Biochem Biophys Res Commun. 427:86–90. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Wang RC, Wei Y, An Z, et al: Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science. 338:956–959. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Xu J, Qian J, Xie X, et al: High density lipoprotein cholesterol promotes the proliferation of bone-derived mesenchymal stem cells via binding scavenger receptor-B type I and activation of PI3K/Akt, MAPK/ERK1/2 pathwys. Mol Cell Biochem. 371:55–64. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Zhang J, Shemezis JR, McQuinn ER, et al: Akt activation by N-cadherin regulates beta-catenin signaling and neuronal differentiation during cortical development. Neural Dev. 8:72013. View Article : Google Scholar : PubMed/NCBI

19 

Wang Z, Havasi A, Gall JM, et al: Beta-catenin promotes survival of renal epithelial cells by inhibiting Bax. J Am Soc Nephrol. 20:1919–1928. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Dihlmann S, Kloor M, Fallsehr C, et al: Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis. 26:1503–1512. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Zhang Y, Yu J, Shi C, et al: Regulatory effect of β-catenin on proliferation of hair follicle stem cells involves PI3K/Akt pathway. J Appl Biomed. 11:131–141. 2013.

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wu J, Niu J, Li X, Ren T and Zhang F: Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells. Mol Med Rep 10: 955-958, 2014.
APA
Wu, J., Niu, J., Li, X., Ren, T., & Zhang, F. (2014). Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells. Molecular Medicine Reports, 10, 955-958. https://doi.org/10.3892/mmr.2014.2286
MLA
Wu, J., Niu, J., Li, X., Ren, T., Zhang, F."Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells". Molecular Medicine Reports 10.2 (2014): 955-958.
Chicago
Wu, J., Niu, J., Li, X., Ren, T., Zhang, F."Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells". Molecular Medicine Reports 10, no. 2 (2014): 955-958. https://doi.org/10.3892/mmr.2014.2286
Copy and paste a formatted citation
x
Spandidos Publications style
Wu J, Niu J, Li X, Ren T and Zhang F: Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells. Mol Med Rep 10: 955-958, 2014.
APA
Wu, J., Niu, J., Li, X., Ren, T., & Zhang, F. (2014). Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells. Molecular Medicine Reports, 10, 955-958. https://doi.org/10.3892/mmr.2014.2286
MLA
Wu, J., Niu, J., Li, X., Ren, T., Zhang, F."Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells". Molecular Medicine Reports 10.2 (2014): 955-958.
Chicago
Wu, J., Niu, J., Li, X., Ren, T., Zhang, F."Downregulation of β-catenin and Akt signaling is responsible for poor proliferation of the late passage of bone marrow mesenchymal stem cells". Molecular Medicine Reports 10, no. 2 (2014): 955-958. https://doi.org/10.3892/mmr.2014.2286
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team